Spotlight Series on Hepatitis C


Fixed-Dose Sofosbuvir/Velpatasvir/Voxilaprevir Cures 97% of Treatment-Experienced Hepatitis C Patients

December 6, 2016

Stefan Zeuzem, M.D.

Stefan Zeuzem, M.D., presenting study results (Credit: Warren Tong)

A fixed-dose combination of sofosbuvir (SOF, Sovaldi), velpatasvir (VEL) and voxilaprevir (VOX) yielded a 97% sustained virologic response rate 12 weeks after treatment ended (SVR12) in patients with direct-acting antiviral (DAA) experience but still naive to NS5A inhibitors. Fixed-dose SOF/VEL (Epclusa) resulted in a 90% SVR12 in the randomized, active-comparator POLARIS-4 trial.

POLARIS-4 investigators noted that a small proportion of hepatitis (HCV) patients do not achieve SVR with their first DAA regimen. They conducted this trial to test two options for patients with DAA experience -- the fixed-dose combination SOF/VEL/VOX and the fixed-dose combination SOF/VEL. SOF is a pangenotypic inhibitor of the HCV NS5B protein, VEL a pangenotypic inhibitor of NS5A and VOX a pangenotypic inhibitor of NS3/4A protease. Participants had DAA experience, but the trial excluded those who had taken an NS5A inhibitor or an NS3/4A inhibitor plus ribavirin (Rebetol) and pegylated interferon.

This open-label trial at 102 sites in North America, Europe, Australia and New Zealand randomized HCV genotype 1, 2 or 3 patients equally to 12 weeks of SOF/VEL/VOX or SOF/VEL, while participants with other genotypes all received SOF/VEL/VOX. The primary endpoint was SVR12, and an efficacy analysis rated each regimen against a prespecified performance goal of 85% at a P value of .025.


Of the 182 participants who started SOF/VEL/VOX and the 151 who started SOF/VEL, age averaged 57 years, about three-quarters were men, 88% were white, 46% had cirrhosis and pretreatment viral load averaged 6.3 log10 IU/mL. In the SOF/VEL/VOX and SOF/VEL groups, respectively, 43% and 43% had genotype 1, 17% and 22% had genotype 2 and 30% and 34% had genotype 3. While 69% of participants had already taken SOF, 11% had taken SOF plus simeprevir (Olysio). All 182 participants who started SOF/VEL/VOX completed treatment, while 149 of 151 who started SOF/VEL completed therapy.

Of the 182 people in the SOF/VEL/VOX arm, 177 (97%) achieved SVR12. Among the five who did not, one relapsed, one died and three were lost to follow-up. Of the 151 in the SOF/VEL arm, 136 (90%) achieved SVR12. Among the 15 who did not, there were 14 relapses and one breakthrough. The performance analysis determined that SOF/VEL/VOX was superior to the prespecified 85% SVR12 goal (P < .001), while SOF/VEL was not (P = .092).

SVR12s with SOF/VEL/VOX and SOF/VEL were 98% and 94% for patients without cirrhosis and 96% and 86% for those with cirrhosis, respectively. Respective SVR12s were 98% and 89% for genotype 1a, 96% and 95% for genotype 1b, 100% and 97% for genotype 2, 94% and 85% for genotype 3 and 100% with SOF/VEL/VOX for genotype 4. With SOF/VEL/VOX, SVR12 was 94% or higher regardless of baseline resistance-associated substitutions. With SOF/VEL, SVR12 was 90% with any resistance-associated substitution and 50% (two of four patients) with NS3 plus NS5A resistance-associated substitutions.

Two participants in each study arm had a grade 3 or 4 adverse event, no one had a drug-related serious adverse event and one person taking SOF/VEL stopped treatment because of an adverse event (headache). Rates of grade 3 lab abnormalities were 5% with SOF/VEL/VOX and 6% with SOF/VEL. One person in each group had a grade 4 lab abnormality. Approximately one-quarter of participants in each study arm reported headache and one-quarter reported fatigue. Diarrhea affected 20% taking SOF/VEL/VOX (86% grade 1).

The POLARIS-4 investigators concluded that "SOF/VEL/VOX for 12 weeks is a highly effective salvage therapy" for DAA-experienced patients who have not taken an NS5A inhibitor.

Mark Mascolini writes about HIV and hepatitis virus infection.

Copyright © 2016 Remedy Health Media, LLC. All rights reserved.

Related Stories

Low Uptake of Direct-Acting Antivirals for Hepatitis C in U.S. Clinics -- Race and Income Key Factors
High Hepatitis C Cure Rates With Harvoni and Viekira Pak in Veterans With Genotype 1
Curing Hepatitis C Lowers but Does Not Eliminate Risk of Liver Cancer

This article was provided by TheBodyPRO. It is a part of the publication The Liver Meeting.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.